First Hawaiian Bank Sells 1,836 Shares of Sanofi $SNY

First Hawaiian Bank lessened its position in Sanofi (NASDAQ:SNY) by 1.6% in the 1st quarter, Holdings Channel.com reports. The fund owned 113,188 shares of the company’s stock after selling 1,836 shares during the period. First Hawaiian Bank’s holdings in Sanofi were worth $6,277,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Accent Capital Management LLC bought a new stake in shares of Sanofi in the 1st quarter worth about $29,000. Eastern Bank increased its stake in Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after buying an additional 300 shares during the period. Golden State Wealth Management LLC increased its stake in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after buying an additional 545 shares during the period. Banque Transatlantique SA purchased a new position in Sanofi in the 1st quarter worth about $33,000. Finally, Brentview Investment Management LLC purchased a new position in Sanofi in the 1st quarter worth about $42,000. Institutional investors own 14.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $56.00 to $58.00 in a research note on Monday. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Sanofi has a consensus rating of “Buy” and an average price target of $62.67.

Sanofi Trading Up 1.0%

NASDAQ SNY opened at $47.65 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The company has a market capitalization of $117.01 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company’s 50-day simple moving average is $48.68 and its two-hundred day simple moving average is $51.21. Sanofi has a one year low of $44.73 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period last year, the business posted $1.73 EPS. Equities analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.